PMC8170330_01
Tomography scan assessments of the right parotid lesion at different time points. (a)
Before starting the first course of carboplatin/cetuximab. (b) After completing five
cycles of carboplatin/cetuximab and before starting the first course of pembrolizumab.
(c) After completing four cycles of pembrolizumab and before starting the first course
of pembrolizumab/cetuximab. (c) Three months and (d) 2 years after introduction of
pembrolizumab/cetuximab.
10.1177_17588359211015493-fig1.jpg
PMC8170330_01_10.1177_17588359211015493-fig1.jpg
fig1-17588359211015493
In June 2018, computed tomography (CT) scan performed after five cycles of treatment showed a mixed response, with 38% shrinkage of the right supraclavicular infiltration and emergence of a new right parotid lesion [Figure 1(a) and (b) and Figure 2(a)]. A new CT scan performed 2 months later (September 2018) confirmed progression 3 months after treatment initiation [Figure 1(c)]. In December 2018, a partial radiological response was observed, associated with major clinical improvement [Figure 1(d) and Figure 2(c)].
Clinical and computed tomography assessments of the right supraclavicular lesion at
different time points. (a) Before starting the first course of pembrolizumab. (b) After
completing four cycles of pembrolizumab and before starting the first course of
pembrolizumab/cetuximab. (c) Three months and (d) 2 years after introduction of
pembrolizumab/cetuximab.
10.1177_17588359211015493-fig2.jpg
PMC8170330_01_10.1177_17588359211015493-fig2.jpg
fig2-17588359211015493
In June 2018, computed tomography (CT) scan performed after five cycles of treatment showed a mixed response, with 38% shrinkage of the right supraclavicular infiltration and emergence of a new right parotid lesion [Figure 1(a) and (b) and Figure 2(a)]. Radiographic progression was associated with decreased performance status secondary to appearance of intense neuralgia following invasion of the brachial plexus, requiring introduction of opioids treatment [Figure 2(b)]. In December 2018, a partial radiological response was observed, associated with major clinical improvement [Figure 1(d) and Figure 2(c)]. In September 2020, a complete clinical and radiological response was still observed, allowing us to stop the immunotherapy [Figure 2(d)].